ArrowMark Colorado Holdings LLC Acquires 28,804 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

ArrowMark Colorado Holdings LLC lifted its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 3.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 787,649 shares of the company’s stock after acquiring an additional 28,804 shares during the period. ArrowMark Colorado Holdings LLC owned approximately 0.92% of Pediatrix Medical Group worth $9,129,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in Pediatrix Medical Group during the 2nd quarter worth $31,000. Innealta Capital LLC bought a new position in shares of Pediatrix Medical Group during the second quarter valued at about $33,000. Quest Partners LLC boosted its holdings in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in Pediatrix Medical Group in the 2nd quarter valued at about $72,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft boosted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. StockNews.com lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Mizuho lifted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Truist Financial increased their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Jefferies Financial Group lifted their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Stock Performance

MD stock opened at $15.01 on Tuesday. The stock has a fifty day moving average of $13.33 and a 200-day moving average of $10.28. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the business earned $0.29 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. As a group, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is owned by company insiders.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.